Diabetic foot ulcer calluses show histological similarities to HPV infection without evidence of HPV involvement by nested PCR

A number of studies have reported an association between callus formation and the development of foot ulcers in diabetic patients. However, it has been noted that calluses may continue to form in spite of bed rest and, presumably, excellent patient compliance with offloading. Additionally, the authors have noted that, histologically, calluses in the diabetic foot often resemble lesions induced by human papillomavirus (HPV). As diabetes is associated with immune depression, the authors hypothesized that HPV may play at least a partial role in the pathogenesis of calluses in diabetic patients. The objective of the reported study was to determine whether calluses around diabetic neuropathic foot ulcers are associated with HPV infection. The authors carried out biopsies on 11 independent calluses from 6 patients with diabetic foot ulcers and analyzed each sample by histology and by nested polymerase chain reaction (PCR), screening for the presence of DNA from HPV-1, -2, -3, -4, -6, -10, -11, -16, -18, -27, -28, -29, -31, -41, -50, -57, -60, -63, -65, and -77. The callus biopsy specimens showed histological evidence of koilocytes, papillary hyperplasia, hypergranulosis, and hyperkeratosis, a picture very similar to HPV cutaneous infection. However, nested PCR using positive and negative controls did not show detectable levels of HPV DNA. The authors therefore conclude that HPV infection is unlikely to play a significant role in diabetic foot callus pathogenesis, in spite of histological findings similar to those seen with verruca vulgaris.

CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation

INTRODUCTION

CIP2A is a newly identified inhibitor of PP2A. It can stabilize c-Myc and promote anchorage-independent cell growth and tumour formation. CIP2A is over-expressed in some solid tumours although its expression in acute myeloid leukaemia (AML) is still unknown.

METHODS

CIP2A mRNA and protein expressions were determined in bone marrow mononuclear cells of both patients with AML and healthy controls using reverse transcription polymerase chain reaction and Western blot, respectively. We used siRNA to knock-down CIP2A expression in HL60 cells and then examined its potential roles during the pathological progression of AML.

RESULTS

CIP2A mRNA was present in 54 of 70 (77.14%) patients with newly diagnosed AML and in 11 of 14 (70.86%) patients with relapsed AML, which was significantly higher than complete remission specimens and healthy controls (P<0.001). Knock-down of CIP2A in HL60 cells slowed down cell proliferation, decreased clonogenic activity and promoted cell differentiation.

CONCLUSION

These results suggest that CIP2A is over-expressed in patients with newly diagnosed/relapsed AML and the expression of CIP2A could have potential use as a clinical marker for AML relapse after treatment. The high expression of CIP2A in HL60 cells may be related to active cell proliferation and arrest of cell differentiation. This study may shed light on the molecular function of CIP2A in myeloid leukemogenesis.

Up-regulation of human arrest-defective 1 protein is correlated with metastatic phenotype and poor prognosis in breast cancer

BACKGROUND

Human arrest defective 1 protein (ARD1), as a N-terminal acetyltransferase, has been reported to play a crucial role in tumorigenesis, but the results are somewhat controversial. To explore the clinical and pathological significance of ARD1 in breast tumorigenesis, we analyzed ARD1 status in multiple types of breast disease.

METHODS

The expression of ARD1 protein was assessed by immunohistochemistry in 356 cases including 82 invasive ductal carcinomas (IDC), 159 fibroadenomas, 66 hyperplasia of mammary glands, 19 inflammatory breast disease, 30 breast cysts, and in 29 postoperative treatment patients. We assessed the relationship of ARD1 protein with clinical and pathological characteristics using χ2 test.

RESULTS

ARD1 protein was observed at 61.0% (50/82), 54.7% (87/159), 37.9% (25/66), 36.8% (7/19) in IDC, fibroadenoma, hyperplasia, and inflammation, respectively, and less than 30.0% for breast cyst. Thus, high ARD1 expression correlated with breast cancer (relative risk = 1.32, P < 0.005). Moreover, the level of ARD1 protein in carcinoma patients was distinctly related to lymph node metastasis and ER status, with 94.0% (47/50) as copmpared to 6.0% (3/50) in metastatic and non-metastatic (P < 0.001), and 84.0% (42/50) and 16.0% (8/50) for ER + and ER - (P < 0.01), respectively. In addition, the level of ARD1 appeared to have potential for evaluation of prognosis in breast cancer patients after postoperative therapy.

CONCLUSIONS

These results suggest that ARD1 expression may be as a potential target for exploring the mechanism of breast cancer metastasic to lymph nodes and hormone-responsive regulation.

A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction

Sixty treatment-seeking individuals with methamphetamine (MA) dependence entered a randomized, placebo-controlled, double-blind clinical trial of oral dextroamphetamine (d-AMP) as a replacement therapy for MA dependence. The subjects took 60 mg sustained-release d-AMP for 8 weeks, during which time they received eight 50-min sessions of individual psychotherapy. Adverse events and urine toxicology for MA were assessed two times a week. There were no serious adverse events. Urine samples containing <1,000 ng/ml of MA were classified as negative for MA. The MA-negative scores in the d-AMP group (3.1 ± SD 4.6) were no higher than those in the placebo group (3.3 ± SD 5.3; P > 0.05). However, withdrawal and craving scores were significantly lower in the d-AMP group (P < 0.05 for both). Although subjects taking d-AMP did not reduce their use of MA, the significant reductions observed in withdrawal and craving scores in this group support the need for further exploration of d-AMP as a pharmacologic intervention for MA dependence, possibly at higher doses.

Search for ZH → l+ l- bb production in 4.2 fb(-1) of pp collisions at sqrt[s] =1 .96 TeV

We present a search for the standard model Higgs boson produced in association with a Z boson in 4.2 fb(-1) of pp collisions, collected with the D0 detector at the Fermilab Tevatron at sqrt[s] =1 .96 TeV. Selected events contain one reconstructed Z → e+ e- or Z → μ+ μ- candidate and at least two jets, including at least one b-tagged jet. In the absence of an excess over the background expected from other standard model processes, limits on the ZH cross section multiplied by the branching ratios are set. The limit at M(H) = 115  GeV is a factor of 5.9 larger than the standard model prediction.

Abstract P1-08-05: The Establishment of Rat Model of Premalignant Breast Disease and Histomorphological Study of Rats’ Premalignant Disease

Background:The treatment of breast cancer requires not only a reasonable strategy, but also effective preventive measures. Study of precancerous lesions can help explore the pathogenesis of breast cancer, and its mechanism is important of vesting. In view of long-term progressive pathological process and many co-exsited factors, it is difficult to observe the process in the human being itself, the establishment of a suitable animal model can surve to provide experimental basis for the prevention of premalignancy of breast cancer's transfer mechanism and have a great value.At present, the establishment of breast hyperplasia animal model is mature and unsuccessful for difficulty to determine the end of experiment.

Methods: 54 SD rats were randomly divided into 7 groups. Observation of GroupII-VII last for 32 weeks.

GroupI:blank control ,NS 1ml ig in the first day,0.5 ml NS intraperitoneal injection at the 2nd -25th days ,then stop for 5 days .30 days is one cycle ,observe 7 cycles.

GroupII: DMBA only.DMBA ig in the first day with the dose of 10mg/kg DMBA GroupIII: DMBA +hormone sequential 5 days.DMBA ig in the first day with the dose of 10mg/kg DMBA ,estradiol benzoate intraperitoneal injection with the dose of 0.5mg/kg.day at the 1st -3rd days. Progestin intraperitoneal injection with the dose of 4mg/kg.day at the 4th day. one cycle was 5 days

GroupIV: DMBA +hormone sequential 30 days.DMBA ig in the first day with the dose of 10mg/kg DMBA ,estradiol benzoate intraperitoneal injection with the dose of 0.5mg/kg.day at the 1st -21st days. Progestin intraperitoneal injection with the dose of 4mg/kg.day at the 22nd-25th days. one cycle was 30 days

Group V:MNU only; DMBA only; MNU ig in the first day with the dose of 5mg/kg .

Group VI: MNU +hormone sequential 5 days.MNU ig in the first day with the dose of 5mg/kg, estradiol benzoate intraperitoneal injection with the dose of 0.5mg/kg.day at the 1st -3rd days. Progestin intraperitoneal injection with VII: MNU +hormone sequential 30 days .,MNU ig in the first day with the dose of 5mg/kg, ,estradiol benzoate intraperitoneal injection with the dose of 0.5mg/kg.day at the 1st -21st days. Progestin intraperitoneal injection with the dose of 4mg/kg.day at the 22nd-25th days. one cycle was 30 days.

After the 14th week, one pair of breast of every group was taken out to perform the histomorphological changes until all the rats were executed in the 32nd week.

Result:The total incidence of premalignant breast disease of DMBA group was 47%, while MNU group 8%,with statistical significance. No statistical significan was observed within the subgroup of DMBA. Most of premalignant lesions occurred during the 20th to 28th weeks. See Table 1.

Pathological results of 7 Groups

Discussion

MNU is not fit for inducing the premalignant lesions of SD rats. DMBA is a better medicine to observe the premalignant lesions of SD rats.

The 20-28 weeks is the best interval to observe the premalignant lesions.

Glutamate transporter type 3 knockout mice have a decreased isoflurane requirement to induce loss of righting reflex

Excitatory amino acid transporters (EAAT) uptake extracellular glutamate, the major excitatory neurotransmitter in the brain. EAAT type 3 (EAAT3), the main neuronal EAAT, is expressed widely in the CNS. We have shown that the volatile anesthetic isoflurane increases EAAT3 activity and trafficking to the plasma membrane. Thus, we hypothesize that EAAT3 mediates isoflurane-induced anesthesia. To test this hypothesis, the potency of isoflurane to induce immobility and hypnosis, two major components of general anesthesia, was compared in the CD-1 wild-type mice and EAAT knockout mice that had a CD-1 strain gene background. Hypnosis was assessed by loss of righting reflex in this study. The expression of EAAT1 and EAAT2, two widely expressed EAATs in the CNS, in the cerebral cortex and spinal cord was not different between the EAAT3 knockout mice and wild-type mice. The concentration required for isoflurane to cause immobility to painful stimuli, a response involving primarily reflex loops in the spinal cord, was not changed by EAAT3 knockout. However, the EAAT3 knockout mice were more sensitive to isoflurane-induced hypnotic effects, which may be mediated by hypothalamic sleep neural circuits. Interestingly, the EAAT3 knockout mice did not have an altered sensitivity to the hypnotic effects caused by ketamine, an i.v. anesthetic that is a glutamate receptor antagonist and does not affect EAAT3 activity. These results suggest that EAAT3 modulates the sensitivity of neural circuits to isoflurane. These results, along with our previous findings which suggests that isoflurane increases EAAT3 activity, indicate that EAAT3 may regulate isoflurane-induced behavioral changes, including anesthesia.

Abstract P1-11-11: Correlation between ER/PgR/Her-2/Ki67 Expression and Response to Neoadjuvant Endocrine Therapy for HR Positive Post-Menopausal Breast Cancer

Background: Endocrine therapy was standard adjuvant treatment for hormone receptor positive breast cancer. However, there were factors other than receptor status could influence endocrine responsiveness. Neoadjuvant therapy was an excellent platform for predictive factors research, but the standard for evaluating the efficacy of neoadjuvant endocrine therapy was controversy. The aim of this study was to investigate the correlation among the results of different response evaluation system, and the relationships between ER/PgR/Her-2/Ki67 expression and the responses to neoadjuvant endocrine therapy for postmenopausal breast cancer.

Methods: Data of consecutive 133 core needle biopsy (CNB) confirmed hormone receptor strongly positive (more than 50% tumor cell stained ER or PgR) postmenopausal breast cancer treated with neoadjuvant endocrine therapy were analysis retrospectively. All pts. were planned to receive endocrine therapy alone as their adjuvant treatment and prescribed Anastrozole 1 mg per day for 16 weeks before surgery. Clinical response were evaluated by using documented ultrasound records,pathological response was evaluated by one senior pathologist with Miller & Payne classification. Cell cycle complete response was defined as post-treatment Ki67 ≥1%. The new slides of pre-treatment and surgical specimens were made for ER/PgR (ER\PR DakoCytomation)/Her-2 (Her-2 Dako HercepTest TM)/Ki67 (Ki67 Ventana) immunohistochemical staining through Benchmark XT Staining Instrument (Ventana Medical Systems. Inc. Arizona. USA) and classified by using image analysis system Ariol (Applied Imaging Inc., San-Jose, California, USA).

Results: Clinical response were CR:0.8% PR:33.1% SD:66.1%, pathological response were G5:3% G4+G3:47.4% G2+G1:49.6%, Ki67 change were &lt;1%: 22.8% decrease but &gt;1%:45.1% no decrease: 32.1%. The correlation and consistency among the response evaluated differently were poor [table 1]. The per-treatment ER/PR/Her-2/Ki67 showed low degree of correlation with responses [table 2]. Pre-treatment ER≥90% and PR≥90% and Her-2 coudln't predict better response.

The correlation and consistency among response evaluated in different system

Conclusion: The correlation and consistency among the results of response to neoadjuvant endocrine therapy evaluated by different system were poor. ER/PgR/Her-2/Ki67 showed low degree of correlation to responses. It's difficult to predict response to Arimidex neoadjuvant endocrine therapy by using ER/PgR/Her-2/Ki67 expression.

Increased levels of soluble vascular endothelial cadherin are associated with poor outcome in severe sepsis

Endothelial cells are thought to play a key role in sepsis pathogenesis: vascular endothelial damage occurs in severe sepsis and multiple organ dysfunction. Soluble vascular endothelial cadherin (VE-cadherin) levels were investigated in a prospective study involving 28 consecutive critically ill patients with or without severe sepsis who were admitted to surgical intensive care; 13 healthy age-matched volunteers were included as controls. Soluble VE-cadherin levels increased significantly in patients with severe sepsis compared with ill patients without severe sepsis and healthy controls. There was a significant linear correlation between soluble VE-cadherin levels and illness severity scores. Soluble VE-cadherin levels were significantly higher in patients who died compared with survivors. In vitro cell culture showed that serum from patients with severe sepsis greatly decreased VE-cadherin staining at intercellular junctions and total VE-cadherin expression in human umbilical cord vein endothelial cells. These findings suggest that endothelial cells play an important role in the poor outcome of patients with severe sepsis.

Electric and magnetic excitation of coherent magnetic plasmon waves in a one-dimensional meta-chain

A one-dimensional diatomic meta-chain with equal-size holes and different-length slits is designed. Broadband coherent magnetic plasmon waves (MPW) are formed in such a system, excited by both the electric resonance in the slits and the magnetic resonance in the holes in a wide range of incidence angles (0°-40°) and broad frequency bands (200-230 THz). The dispersion properties of the MPW measured in our experiments agree with the theoretical calculation based on the Lagrange model. The coherent MPWs reported in this paper may have applications in subwavelength integrated nanocircuits.

Search for diphoton events with large missing transverse energy in 6.3 fb(-1) of pp collisions at √s=1.96 TeV

We report a search for diphoton events with large missing transverse energy produced in pp collisions at √s=1.96  TeV. The data were collected with the D0 detector at the Fermilab Tevatron Collider and correspond to 6.3  fb(-1) of integrated luminosity. The observed missing transverse energy distribution is well described by the standard model prediction, and 95% C.L. limits are derived on two realizations of theories beyond the standard model. In a gauge-mediated supersymmetry breaking scenario, the breaking scale Λ is excluded for Λ<124  TeV. In a universal extra dimension model including gravitational decays, the compactification radius R(c) is excluded for R(c)(-1)<477  GeV.

RMI1 attenuates tumor development and is essential for early embryonic survival

RMI1/BLAP75 (RecQ-mediated genome instability 1/Bloom-associated protein 75) is an OB-fold protein highly conserved from yeast to human. Previous studies showed that RMI1 is required for the stability of the BLM/RMI1/Top3α complex and for the suppression of elevated sister chromatids exchange (SCE). The presence of RMI1 strongly stimulates Holliday dissolution activity of the Bloom helicase in vitro. The in vivo function of RMI1, however, remains largely undefined. To address this question, we generated RMI1 knockout mice through homologous replacement targeting. We found that, while RMI1 +/⁻ mice showed no obvious developmental phenotype, deletion of both mRMI1 alleles resulted in early embryonic lethality before implantation. To determine whether RMI1 plays a role in tumorigenesis, we generated RMI1/p53 double heterozygous mice and analyzed their onset of ionizing radiation-induced tumor development. RMI1 +/⁻/p53 +/⁻ mice succumbed to tumor with a higher frequency and exhibited a substantially shortened survival when compared to the wild type, RMI1 +/⁻ and p53 +/⁻ cohorts. These results demonstrated a dual-role of RMI1 in embryonic development and tumor suppression.

Search for new fermions ("quirks") at the Fermilab Tevatron collider

We report results of a search for particles with anomalously high ionization in events with a high transverse energy jet and large missing transverse energy in 2.4 fb⁻¹ of integrated luminosity collected by the D0 experiment at the Fermilab Tevatron pp collider. Production of such particles (quirks) is expected in scenarios with extra QCD-like SU(N) sectors, and this study is the first dedicated search for such signatures. We find no evidence of a signal and set a lower mass limit of 107, 119, and 133 GeV for the mass of a charged quirk with strong dynamics scale Λ in the range from 10 keV to 1 MeV and N=2, 3, and 5, respectively.

High-fidelity conformation of graphene to SiO2 topographic features

High-resolution noncontact atomic force microscopy of SiO2 reveals previously unresolved roughness at the few-nm length scale, and scanning tunneling microscopy of graphene on SiO2 shows graphene to be slightly smoother than the supporting SiO2 substrate. A quantitative energetic analysis explains the observed roughness of graphene on SiO2 as extrinsic, and a natural result of highly conformal adhesion. Graphene conforms to the substrate down to the smallest features with nearly 99% fidelity, indicating conformal adhesion can be highly effective for strain engineering of graphene.

Search for events with leptonic jets and missing transverse energy in pp collisions at √s=1.96 TeV

We present the first search for pair production of isolated jets of charged leptons in association with a large imbalance in transverse energy in pp collisions using 5.8 fb⁻¹ of integrated luminosity collected by the D0 detector at the Fermilab Tevatron Collider. No excess is observed above the standard model background, and the result is used to set upper limits on the production cross section of pairs of supersymmetric chargino and neutralino particles as a function of "dark-photon" mass, where the dark photon is produced in the decay of the lightest supersymmetric particle.

Measurement of the bottom quark contribution to nonphotonic electron production in p + p collisions at √s=200 GeV

The contribution of B meson decays to nonphotonic electrons, which are mainly produced by the semileptonic decays of heavy-flavor mesons, in p + p collisions at √s=200  GeV has been measured using azimuthal correlations between nonphotonic electrons and hadrons. The extracted B decay contribution is approximately 50% at a transverse momentum of pT≥5  GeV/c. These measurements constrain the nuclear modification factor for electrons from B and D meson decays. The result indicates that B meson production in heavy ion collisions is also suppressed at high pT.

Inhibition of Grb2 expression demonstrates an important role in BCR-ABL-mediated MAPK activation and transformation of primary human hematopoietic cells

Chronic myeloid leukemia (CML) results from the expression of the BCR/ABL oncogene in a primitive hematopoietic cell. However, BCR/ABL-activated signaling mechanisms are dependent on the cellular context in which it is expressed, and mechanisms underlying primitive human hematopoietic cell transformation by BCR-ABL are not well understood. Our previous studies have shown that BCR/ABL-Y177 has an essential role in Ras activation and human hematopoietic progenitor transformation in CML. The adapter protein growth factor receptor-binding protein-2 (Grb2) can bind phosphorylated BCR/ABL-Y177, induce Grb2-SoS complex formation and activate Ras signaling. We investigated the role of Grb2 in CML progenitor transformation by cotransducing human CD34+ cells with lentivirus vectors expressing short hairpin RNA to Grb2 and retrovirus vectors expressing BCR/ABL. We show that Grb2 knockdown significantly inhibits proliferation and survival of BCR-ABL-expressing CD34+ cells, but not control CD34+ cells. Grb2 knockdown reduced mitogen-activated protein kinase (MAPK) activity in BCR-ABL-expressing hematopoietic cells. We conclude that inhibition of Grb2 expression demonstrates an important role in BCR-ABL-mediated MAPK activation and transformation of primary human hematopoietic cells.These results support further investigation of downstream effectors of Grb2-mediated signals and targeting of Grb2 interactions in the treatment of CML.

Search for sneutrino production in eμ final states in 5.3 fb-1 of pp collisions at square root s =1.96 TeV

We report the results of a search for R parity violating (RPV) interactions leading to the production of supersymmetric sneutrinos decaying into eμ final states using 5.3 fb-1 of integrated luminosity collected by the D0 experiment at the Fermilab Tevatron Collider. Having observed no evidence for production of eμ resonances, we set direct bounds on the RPV couplings λ311' and λ312 as a function of sneutrino mass.

Comparison of performance of one-color and two-color gene-expression analyses in predicting clinical endpoints of neuroblastoma patients

Microarray-based prediction of clinical endpoints may be performed using either a one-color approach reflecting mRNA abundance in absolute intensity values or a two-color approach yielding ratios of fluorescent intensities. In this study, as part of the MAQC-II project, we systematically compared the classification performance resulting from one- and two-color gene-expression profiles of 478 neuroblastoma samples. In total, 196 classification models were applied to these measurements to predict four clinical endpoints, and classification performances were compared in terms of accuracy, area under the curve, Matthews correlation coefficient and root mean-squared error. Whereas prediction performance varied with distinct clinical endpoints and classification models, equivalent performance metrics were observed for one- and two-color measurements in both internal and external validation. Furthermore, overlap of selected signature genes correlated inversely with endpoint prediction difficulty. In summary, our data strongly substantiate that the choice of platform is not a primary factor for successful gene expression based-prediction of clinical endpoints.

Diagnostic value of adenosine deaminase in cerebrospinal fluid for tuberculous meningitis: a meta-analysis

OBJECTIVE

To determine the accuracy of adenosine deaminase (ADA) measurements in the diagnosis of tuberculous meningitis (TBM).

DESIGN

After a systematic review of English language studies, the sensitivity, specificity and accuracy of ADA concentrations in the diagnosis of cerebrospinal fluid (CSF) were evaluated using random effects models. Summary receiver operating characteristic curves were used to summarise overall test performance.

RESULTS

Ten studies met our inclusion criteria. The sensitivity of ADA in the diagnosis of TBM was 0.79 (95%CI 0.75-0.83), specificity 0.91 (95%CI 0.89-0.93), positive likelihood ratio 6.85 (95%CI 4.11-11.41), negative likelihood ratio 0.29 (95%CI 0.19-0.44) and diagnostic odds ratio 26.93 (95%CI 12.73-56.97).

CONCLUSION

Our data suggest that ADA in the CSF can be a sensitive and specific target and a critical criteria for the diagnosis of TBM.